Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim (G-CSF) in Mild to Moderate Alzheimer's Disease
NCT03656042Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2009
- Primary completion
- Jul 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of filgrastim in Alzheimer's disease (AD) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale, Cognitive subscale - Chinese version at 24 weeks. Started Mar 2009; status: completed.
02
Drugs
filgrastim
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03656042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656042.